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Introduction
Small G proteins act as molecular switches that couple extra­
cellular signals to diverse cellular responses by cycling between 
an inactive GDP­bound and active GTP­bound conformation. 
This activation cycle is regulated by guanine nucleotide exchange 
factors (GEFs), which induce dissociation of the bound nucleo­
tide and its replacement by the more abundant GTP. The result­
ing conformational change allows the binding of effector proteins 
and induction of downstream signaling. Conversely, GTPase­
activating proteins (GAPs) stimulate GTP hydrolysis and, thereby, 
inactivation of the G protein. Together, GEFs and GAPs estab­
lish both temporal and spatial control of G protein signaling. 
They are typically multidomain proteins, and signaling pathways 
that impinge on G proteins do so mainly by regulating the activ­
ity and localization of the associated GEFs and GAPs. This regula­
tion includes the binding of second messengers, posttranslational 
modifications, and their interaction with proteins and lipids 
(Bos et al., 2007).
Exchange protein directly activated by cAMP1 (Epac1) 
and Epac2 are GEFs for small G proteins of the Rap family 
(de Rooij et al., 1998; Kawasaki et al., 1998) and, thereby, 
function  in  cellular  processes  ranging  from  exocytosis  to 
cell–cell junction formation and cell–extracellular matrix ad­
hesion (Gloerich and Bos, 2010). The activity of Epac is directly 
regulated by the second messenger cAMP. cAMP is produced by 
hormone receptor–activated adenylate cyclases and becomes 
compartmentalized because of its local degradation by phos­
phodiesterases (Baillie, 2009). Similar to other GEFs for Ras­
like small G proteins, activity of Epac is mediated by a CDC25 
homology domain (CDC25­HD), which is stabilized by a Ras 
exchange  motif  (REM)  domain.  In  the  autoinhibited  state,   
the catalytic site within the CDC25­HD is sterically covered 
by the N­terminal regulatory region, which harbors a DEP 
(Disheveled, Egl­10, and Pleckstrin) domain and one or two cyclic 
nucleotide­binding domains in Epac1 and Epac2, respectively. 
As demonstrated by the crystal structures of both active and 
inactive Epac2, autoinhibition is released by a conformational 
change induced by binding of cAMP (Rehmann et al., 2006, 
2008). In addition, cAMP establishes spatial control of Epac1, 
as  the  cAMP­induced  conformational  change  induces  the 
translocation of Epac1 to the plasma membrane (Ponsioen et al., 
2009). This membrane recruitment is mediated by the DEP 
domain and is required for efficient Rap activation at the plasma 
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RanBP2 (Nup358) is a cytosolic component of the nuclear   
pore complex (NPC; Wu et al., 1995; Yokoyama et al., 1995). 
RanBP2  was  originally  described  as  a  regulator  of  nucleo­
cytoplasmic transport based on its link with the small G protein 
Ran and the presence of docking motifs for nuclear transport 
receptors (Melchior et al., 1995; Singh et al., 1999; Yaseen 
and Blobel, 1999; Bernad et al., 2004; Forler et al., 2004;   
Hutten  et  al.,  2008,  2009).  The  multidomain  structure  of 
RanBP2 (Fig. 1 A) suggested a more pleiotropic function for this 
membrane  and,  consequently,  Rap­mediated  cell  adhesion 
(Ponsioen et al., 2009). Alternative anchoring mechanisms 
further control the cellular distribution of Epac1, which may 
reflect the diverse functions assigned to this GEF. For instance, 
plasma membrane recruitment by activated ERM (ezrin, ra­
dixin, and moesin) proteins also couples Epac1 activity to cell 
adhesion (Gloerich et al., 2010), whereas nuclear Epac1 regu­
lates the DNA damage­responsive protein kinase (DNA­PK; 
Huston et al., 2008).
Figure 1.  Epac1 directly interacts with the ZNF domain of RanBP2. (A) Domain architecture of RanBP2 with the fragments of RanBP2 isolated in a yeast 
two-hybrid screen using full-length Epac1 as bait shown below. RBD, Ran-binding domain; ZNF, zinc finger; IR, internal repeat domain; CHD, cyclophilin 
homology domain. (B) Coimmunoprecipitation of endogenous RanBP2 with HA-tagged Epac1 in HEK293T cells. Note that besides a major band of 358 kD   
(asterisks in B–D), multiple additional bands of RanBP2 are present on a 6% SDS-PAGE gel, which all disappear upon siRNA-mediated depletion of RanBP2 
(Fig. S1 B). (C) Coimmunoprecipitation of endogenous RanBP2 with Epac1, which was immunoprecipitated with a rabbit polyclonal Epac1 antibody but 
not with preimmune serum (N.I., nonimmune) in Ovcar3 cells. (D) Coimmunoprecipitation of endogenous RanBP2 with HA-tagged Epac1 but not with 
HA-tagged Epac2 in HEK293T cells. (E) Coimmunoprecipitation of the YFP-tagged ZNF domain of RanBP2 with Flag-tagged Epac1 in HEK293T cells.   
(F) Coimmunoprecipitation of a YFP-tagged version of one on the individual ZNFs (ZNF #2) of RanBP2 with HA-tagged Epac1 in HEK293T cells. (G) Pull-
down of bacterially purified Epac1 with the GST-tagged bacterially purified ZNF domain of RanBP2 and, conversely, the ZNF domain with Epac1. Proteins 
were visualized by simply blue staining. EV, empty vector; IB, immunoblot; IP, immunoprecipitation; TL, total lysate.1011 Inhibition of Epac1 by RanBP2 • Gloerich et al.
2008), and indeed, in addition to the cytosol and the nucleus, a 
large fraction of YFP­Epac1 is present at the nuclear envelope 
in HEK293T cells (Fig. 2 A). Strikingly, at low expression 
levels, YFP­Epac1 is detectable solely at this compartment, 
implying a high affinity of Epac1 for its anchor at the nuclear 
envelope (Fig. 2 A). We examined whether RanBP2 functions 
as an anchoring protein for Epac1 at this cellular compart­
ment. For this, HEK293T cells were transfected with YFP­
tagged Epac1, and upon fixation, cells were immunolabeled 
for endogenous RanBP2. This revealed the presence of exog­
enous Epac1 within the cytosol and nucleus and a large frac­
tion of Epac1 that colocalized with RanBP2 at the nuclear 
envelope (Fig. 2 B). To test whether RanBP2 is required for 
the targeting of Epac1 to the NPC, HEK293T cells were de­
pleted  of  RanBP2  by  siRNA­mediated  knockdown  of  the 
protein. Importantly, other nuclear pore components are not 
affected by cellular depletion of RanBP2 (Walther et al., 2002). 
RanBP2 down­regulation resulted in a complete loss of YFP­
Epac1 from the nuclear envelope and the enrichment of Epac1 
in the cytosol and nucleus (Fig. 2 B). Similarly, YFP­Epac1 
localized in a RanBP2­dependent manner at the nuclear enve­
lope in a variety of other cell lines tested, including U2OS cells   
(Fig. 2 C). As expected, Epac2, which does not interact with 
RanBP2 (Fig. 1 D), was not present at the nuclear envelope 
(Fig. S2). To confirm that RanBP2­mediated targeting of Epac1 
to the NPC also occurs endogenously, fixed Ovcar3 cells were 
immunolabeled for both Epac1 and RanBP2. This revealed 
the presence of endogenous Epac1 at the nuclear envelope, 
which disappeared upon siRNA­mediated depletion of RanBP2 
from these cells (Fig. 2 D). To validate this role of RanBP2 in the 
targeting of Epac1, we introduced the ZNFs of RanBP2 linked to 
the CAAX motif of K­Ras into HEK293Ts. This chimera local­
izes to the plasma membrane and, indeed, recruits Epac1 to this 
compartment as well (Fig. 2 E). In conclusion, these data show that 
RanBP2 functions as an anchoring protein for Epac1 at the NPC.
Epac1 remains bound to RanBP2 at the 
NPC upon cAMP binding
The cAMP­induced conformational change of Epac1 not only 
results in its activation but also in its translocation to the plasma 
membrane (Ponsioen et al., 2009). Potentially, RanBP2­bound 
Epac1 also may be released upon cAMP binding and become 
redistributed to the plasma membrane. To test whether acti­
vated Epac1 remains associated with RanBP2, HEK293T cells 
were transfected with Flag­tagged Epac1, and its binding to 
RanBP2  was  determined  upon  stimulation  with  the  Epac­ 
selective cAMP analogue 8­pCPT­2­O­Me­cAMP (007). After 
prolonged stimulation (up to 1 h) with 007, Flag­Epac1 re­
tained its ability to coimmunoprecipitate RanBP2 to a similar 
extent as in unstimulated cells (Fig. 3 A). In addition, the 
presence of Epac1 at the NPC during its activation by cAMP 
was visualized by live imaging of HEK293T cells transfected 
with YFP­tagged Epac1. Although 007 stimulation resulted in 
the relocalization of the cytosolic fraction of Epac1 to the plasma 
membrane, the localization of Epac1 at the NPC remained un­
affected (Fig. 3 B). These data indicate that Epac1 remains 
targeted to NPC by RanBP2 independent of cAMP signaling.
nucleoporin, and RanBP2 is now recognized as a regulator of 
various proteins that each associate with a selective domain of 
RanBP2. For instance, the cyclophilin homology domain is im­
plicated in the interconversion of retinal opsins (Ferreira et al., 
1996, 1997), the leucine­rich domain suppresses activity of   
mitochondrial Cox11 (Aslanukov et al., 2006), and the internal 
repeat domain binds Ubc9 and functions as an E3 SUMO ligase 
(Pichler et al., 2002). By regulating the localization and func­
tion of these proteins, RanBP2 serves in a multitude of cellular 
processes that range from nuclear envelope assembly (Salina 
et al., 2003; Prunuske et al., 2006) to mitosis (Salina et al., 
2003; Dawlaty et al., 2008; Klein et al., 2009; Splinter et al., 
2010) and glucose metabolism (Aslanukov et al., 2006). Here, 
we demonstrate a novel function for RanBP2 as a negative regu­
lator of cAMP signaling through the tethering of Epac1 to the 
NPC and direct inhibition of its catalytic activity.
Results
Epac1 directly interacts with the zinc 
finger (ZNF) domain of RanBP2
To identify novel Epac1­interacting proteins, a yeast two­hybrid 
screen was performed using a human placenta cDNA library and 
full­length Epac1 as bait. Multiple positive clones were isolated 
containing partial cDNAs that encode for the nuclear pore com­
ponent RanBP2. All isolated cDNAs of RanBP2  contained  a 
fragment of its ZNF domain that consists of eight individual 
ZNFs, implying that binding to Epac1 is mediated by the ZNFs 
of RanBP2 (Fig. 1 A). To confirm the interaction of Epac1 with 
RanBP2 in mammalian cells, HA­tagged Epac1 was immuno­
precipitated from HEK293T cells, which showed the coimmuno­
precipitation of endogenous RanBP2 (Fig. 1 B and Fig. S1,   
A and B). Also, in other mammalian cell lines, including U2OS 
cells, we could confirm the interaction between exogenous Epac1 
and RanBP2 (Fig. S1 C). Similarly,  immunoprecipitation  of 
endogenous Epac1 from Ovcar3 cells revealed the binding of 
RanBP2, demonstrating that RanBP2 and Epac1 interact in cells 
endogenously (Fig. 1 C). In contrast, HA­tagged Epac2 was un­
able to coimmunoprecipitate RanBP2 from HEK293T cells, indi­
cating that the binding of RanBP2 is selective for Epac1 (Fig. 1 D). 
As the yeast two­hybrid results implied the binding of Epac1 to 
the ZNFs of RanBP2, HEK293T cells were transfected with Flag­
tagged Epac1 together with the YFP­tagged ZNF domain or with 
an  individual  ZNF  of  RanBP2  (YFP­ZNF).  Indeed,  immuno­
precipitation of Flag­Epac1 demonstrated the binding of both of 
these fragments (Fig. 1, E and F). To exclude that the interaction 
requires additional proteins that are conserved in Saccharomyces 
cerevisiae, we tested the binding between both proteins in vitro 
using bacterially purified Epac1 and the ZNF domain of RanBP2. 
This demonstrated the ability of both purified proteins to interact 
(Fig. 1 G), confirming the direct interaction between the ZNFs of 
RanBP2 and Epac1.
RanBP2 recruits Epac1 to the NPC
RanBP2  constitutes  the  cytoplasmic  filaments  of  the  NPC 
(Delphin et al., 1997; Walther et al., 2002). Also, Epac1 has been 
reported to localize to the NPC (Wang et al., 2006; Brock et al., JCB • VOLUME 193 • NUMBER 6 • 2011   1012
Phosphorylation of the ZNFs of RanBP2 
releases Epac1 from the NPC
Epac1 remains associated with RanBP2 upon cAMP binding, 
but alternative signaling pathways may impinge on RanBP2 or 
Epac1 to affect their interaction. During mitosis, the nuclear en­
velope is broken down, and NPCs are disintegrated, which in­
volves the posttranslational modification of diverse nucleoporins 
by mitotic kinases (Tran and Wente, 2006; Antonin et al., 2008). 
RanBP2 and Epac1 display a distinct localization pattern in mi­
tosis, with RanBP2 being enriched at the kinetochores (Salina 
et al., 2003; Joseph et al., 2004) and Epac1 localizing at the mi­
totic spindle and centrosomes (Qiao et al., 2002). This suggests 
that Epac1 is released from RanBP2 during this phase of the cell 
cycle, which might reveal a potential regulatory mechanism for 
their interaction. Therefore, we examined the binding of Epac1 
to RanBP2 in mitotic cells. U2OS cells were transfected with 
Flag­tagged Epac1 and arrested in mitosis by treatment with 
the microtubule­destabilizing agent nocodazole after a thymi­
dine release. Subsequently, mitotic cells were collected by mi­
totic shake off, and the binding of RanBP2 to Flag­Epac1 was 
tested. As hypothesized, mitotic arrested cells displayed a large 
decrease in the Epac1–RanBP2 interaction compared with un­
synchronized cells (Fig. 4 A). Likewise, when U2OS cells were 
arrested in mitosis by taxol or noscapine, the interaction between 
Epac1 and endogenous RanBP2 was diminished (Fig. S3). In­
terestingly, RanBP2 displayed a decreased electrophoretic mo­
bility in mitotic cells, suggesting its increased phosphorylation 
in mitosis similar to other nucleoporins (Fig. 4 A and Fig. S3). 
The contribution of this potential phosphorylation to the loss 
of Epac1 binding was tested by treatment of cell lysates from 
mitotic cells with ­phosphatase before coimmunoprecipitation.   
­Phosphatase reverted the band shift of endogenous RanBP2 
and, moreover, restored the interaction between Epac1 and 
RanBP2 (Fig. 4 B). Importantly, YFP­ZNF also displayed a de­
creased electrophoretic mobility and reduced binding to Epac1 
in nocodazole­arrested cells (Fig. 4 C). This suggests that Epac1 
is released from RanBP2 by phosphorylation of the ZNFs. To 
verify this, binding of Flag­Epac1 to YFP­ZNF was tested upon 
stimulation of cells with the phosphatase inhibitor okadaic acid 
(OA). By inhibiting protein phosphatase 1 and 2A (Cohen et al., 
1990), OA stimulation decreases protein dephosphorylation 
and results in the elevated phosphorylation state of proteins.   
Indeed, YFP­ZNF as well as Flag­tagged Epac1 displayed a band 
shift upon treatment of HEK293T cells with OA (Fig. 4 D). 
Figure 2.  RanBP2 recruits Epac1 to the NPC. (A) Live imaging of YFP-
Epac1 together with the nuclear marker H2B-RFP in HEK293T cells showing 
the localization of Epac1 in the cytosol, the nucleus, and at the nuclear 
envelope.  (B–D)  Localization  of  YFP-Epac1  in  HEK293T  cells  (B)  and 
U2OS cells (C) and of endogenous Epac1 in Ovcar3 cells (D). Cells were 
transfected with either control (scr, scrambled) or RanBP2 siRNAs, and the 
HEK293T and U2OS cells were transfected the next day with YFP-Epac1. 
60 h after siRNA transfection, cells were fixed and stained for endogenous 
RanBP2 with the goat polyclonal RanBP2 antibody and also for endog-
enous Epac1 in the Ovcar3 cells. Epac1 colocalizes with RanBP2 at the 
nuclear envelope, which is dependent on the presence of the RanBP2. 
(E) Live imaging of CFP-Epac1 together with YFP–empty vector–CAAX or 
YFP-ZNF-CAAX in HEK293T cells. Targeting of the ZNFs of RanBP2 to the 
plasma membrane by addition of the CAAX motif of K-Ras recruits Epac1 
to the plasma membrane as well. Bars, 10 µm.
 1013 Inhibition of Epac1 by RanBP2 • Gloerich et al.
Figure 3.  Epac1 remains bound to RanBP2 at the NPC upon cAMP binding. (A) Coimmunoprecipitation of endogenous RanBP2 with Flag-tagged Epac1 
in HEK293T cells after stimulation with 100 µM 8-pCPT-2-O-Me-cAMP (007) for the indicated time points. (B) Confocal live imaging of HEK293T cells 
transfected with YFP-Epac1 before and 10 min after stimulation with 1 µM 8-pCPT-2-O-Me-cAMP-AM (007-AM). Although the cytosolic fraction of Epac1 
relocalizes to the plasma membrane upon 007-AM stimulation, its localization at the nuclear envelope remains unaltered. Bar, 5 µm. IB, immunoblot;   
IP, immunoprecipitation; TL, total lysate.
Immunoprecipitation of Flag­Epac1 after OA treatment dem­
onstrated a significant decrease in the binding of YFP­ZNF 
(Fig. 4 D). Similar results were obtained with an alternative 
protein phosphatase inhibitor Calyculin A (unpublished data). In 
line with these binding experiments, live imaging of YFP­Epac1 
in HEK293T cells revealed the release of Epac1 from the nuclear 
envelope upon OA stimulation (Fig. 4 E). To confirm that Epac1 
is indeed released by phosphorylation of the ZNFs and exclude a 
contribution of Epac1 modification, HEK293T cells were trans­
fected with either Flag­tagged Epac1 or the YFP­tagged ZNF. 
Next, either the Epac1­ or ZNF­transfected cells, or both, were 
subjected to OA treatment, resulting in selective phosphoryla­
tion of Flag­Epac1 or YFP­ZNF. Upon mixture of the lysates, the 
subsequent coimmunoprecipitation revealed that OA stimulation 
of YFP­ZNF–expressing cells, but not Flag­Epac1–expressing 
cells, decreases the Epac1–ZNF interaction (Fig. 4 F). Thus, we 
demonstrate that the pool of Epac1 bound to RanBP2 at the NPC 
can be released by phosphorylation of the ZNFs. It should be 
noted that although we have identified this regulation to occur 
downstream of mitotic signaling pathways, the involved kinases 
are currently unclear, and other kinase­mediated pathways may 
impinge on the interaction as well.
RanBP2 binds to the CDC25-HD of Epac1
To examine which region of Epac1 is responsible for NPC an­
choring, several truncated versions of Epac1 were tested for 
RanBP2 binding. In contrast to the regulatory region, the cata­
lytic region was able to coimmunoprecipitate RanBP2 from 
HEK293T cells similar to full­length Epac1 (Fig. 5, A and B). 
Further truncation of this region into the individual domains 
revealed that the CDC25­HD is mediating the interaction with 
RanBP2 (Fig. 5 B). Accordingly, both the YFP­tagged catalytic 
region as well as the CDC25­HD localized to the nuclear mem­
brane in these cells (Fig. 5 C). Although the Ras association 
(RA) domain of Epac1 has been implicated previously in NPC 
targeting through binding to the small G protein Ran (Liu et al., 
2010), the individual RA domain does not localize to the nuclear 
envelope (Fig. 5 C). Furthermore, a mutant of Epac1 in which 
the RA region is replaced by the region linking the REM domain 
and the CDC25­HD of the Ras GEF Sos (son of sevenless) still   
localizes to the nuclear envelope similar to wild­type Epac1   
(Fig. 5 D). In line with this, siRNA­mediated depletion of Ran 
did  not  affect  the  presence  of  Epac1  at  the  nuclear  envelope   
(Fig. S4). This indicates that RanBP2 is sufficient for the localiza­
tion of Epac1 at the NPC and functions independently of Ran.
RanBP2 binding inhibits GEF activity  
of Epac1
Because the CDC25­HD is catalyzing the nucleotide exchange 
of Rap, the interaction of RanBP2 with this domain might 
affect the ability of Epac1 to activate Rap. Therefore, the effect 
of RanBP2 binding on the activity of Epac1 was tested in vitro. 
For this, bacterially purified Epac1 was incubated with Rap1B 
loaded with fluorescently labeled mantGDP in the presence of 
excess unlabeled GDP. The exchange of Rap­bound mantGDP 
by cAMP­activated Epac1 was measured as a decrease in fluores­
cence, both in the absence or presence of increasing amounts 
of the ZNF domain of RanBP2. This revealed that the ZNF do­
main  inhibited  the  activity  of  Epac1  toward  Rap  (Fig.  6 A).   
Importantly, the activity of Epac2 was not altered by the pres­
ence of the RanBP2 ZNF domain (Fig. 6 A), which is compat­
ible with the notion that Epac2 does not interact with RanBP2   
(Fig. 1 D). To confirm this inhibitory function for RanBP2 in vivo, 
we tested the activity of Epac1 after its activation by physiologi­
cal levels of cAMP in Ovcar3 cells upon depletion of RanBP2. 
Activation of Epac1 by stimulation of the  adrenergic receptor 
with isoproterenol increased Rap1­GTP levels in these cells, and 
this was diminished upon siRNA­mediated depletion of Epac1   
(Fig. 6 B). Instead, Epac1­induced Rap1 activation was signifi­
cantly enhanced after knockdown of RanBP2, indicating the in­
creased pool of cellular Epac1 that is capable of activating Rap1 
upon RanBP2 depletion (Fig. 6 B). To verify that RanBP2 binding 
also functionally impedes Epac1 signaling, Epac1­induced adhe­
sion of Ovcar3 cells to the extracellular matrix protein fibronectin 
was measured. In accordance with the Rap­GTP pull­down experi­
ment, depletion of Epac1 abolished isoproterenol­induced adhe­
sion of Ovcar3 cells, whereas this was significantly enhanced by 
knockdown of RanBP2 (Fig. 6 C). Thus, by interacting with the 
CDC25­HD of Epac1, RanBP2 functions as a negative regulator of 
Epac1 and establishes an inactive pool of this GEF at the NPC.JCB • VOLUME 193 • NUMBER 6 • 2011   1014
Figure 4.  Phosphorylation of the ZNFs of RanBP2 releases Epac1 from the NPC. (A) Coimmunoprecipitation of endogenous RanBP2 with Flag-tagged 
Epac1 in U2OS cells that were arrested in mitosis by 24-h incubation with 2.5 µM thymidine, washed three times with PBS, and incubated for 16 h with 
250 ng/ml nocodazole. Mitotic cells were subsequently collected by mitotic shake off and subjected to coimmunoprecipitation. (B) Coimmunoprecipitation 
of endogenous RanBP2 with Flag-tagged Epac1 in U2OS cells that were arrested in mitosis similar to panel A but with treatment of the lysate with 1 µM 
-phosphatase for 30 min before immunoprecipitation of Flag-Epac1. The quantification shows the mean with standard deviation of the relative binding 
of RanBP2 to Flag-Epac1 from three independent experiments. Statistical analysis was performed using a one-tailed Student’s t test. Asterisks indicate the   
p-value of the respective sample with the associated control sample. *, P < 0.007; **, P < 0.0005. (C) Coimmunoprecipitation of the YFP-tagged individual 
ZNF (ZNF #2) of RanBP2 (YFP-ZNF) with Epac1 in U2OS cells that were arrested in mitosis similar to panel A. (D) Coimmunoprecipitation of the YFP-tagged 
individual ZNF (ZNF #2) of RanBP2 (YFP-ZNF) with Flag-tagged Epac1 in HEK293T cells after stimulation with the phosphatase inhibitor okadaic acid   
(OA; 1 µM) for 1 h. OA results in a decrease in electrophoretic mobility of both YFP-ZNF and Flag-Epac1 and a decrease in association of the two proteins.   
(E) Confocal live imaging of HEK293T cells transfected with YFP-Epac1 before and 1 h after stimulation with 1 µM OA. This shows the decreased presence 
of Epac1 at the nuclear envelope upon OA stimulation. Note that also the plasma membrane localization of Epac1 is affected by OA stimulation, whereas 
an increase in cytosolic YFP-Epac1 is observed. Bar, 2 µm. (F) Coimmunoprecipitation of YFP-ZNF with Flag-tagged Epac1 after selective induction of 
phosphorylation of either YFP-ZNF or Flag-Epac1 by OA. Two separate dishes of HEK293T cells were transfected with either YFP-ZNF or Flag-Epac1 where 
indicated, and either one of the two or both were stimulated with 1 µM OA. Subsequently, the cell lysates of YFP-ZNF– and Flag-Epac1–expressing cells 
were mixed and subjected to coimmunoprecipitation. This demonstrates that OA stimulation of YFP-ZNF–transfected cells, but not Flag-Epac1–transfected 
cells, inhibits the binding between the two proteins. The quantification shows the mean with standard deviation of the relative binding of YFP-ZNF to Flag-
Epac1 from three independent experiments. Statistical analysis was performed using a one-tailed Student’s t test. *, P < 0.0001. The minus signs indicate 
unstimulated cells. IB, immunoblot; IP, immunoprecipitation; TL, total lysate.1015 Inhibition of Epac1 by RanBP2 • Gloerich et al.
interacts with the catalytic CDC25­HD of Epac1, resulting in 
the inhibition of the catalytic activity of Epac1 toward Rap1 
in vitro. Finally, we show that depletion of RanBP2 liberates 
Epac1 from the NPC and enhances Epac1­dependent cAMP 
responses, i.e., induction of Rap1 activity and, consequently, 
cell–extracellular matrix adhesion. Thus, RanBP2 establishes 
an inactive pool of Epac1 at the NPC, which upon release, may 
enhance cAMP­Epac1­Rap signaling. Collectively, these results 
show, for the first time, that components of the NPC function to 
maintain an inactive state of GEFs in the cell.
Our results show that the ZNFs of RanBP2 directly inhibit 
Epac1 activity by binding to the catalytic CDC25­HD of Epac1. 
Elucidation of the mechanism awaits structural analysis of the 
complex, but RanBP2 may reorient the Rap­binding surfaces 
within the CDC25­HD or, alternatively, prevent Rap binding by 
steric hindrance. Clearly, this interaction is regulated, and our 
data indicate that this regulation includes the phosphorylation 
of the ZNFs of RanBP2 (Fig. 4). First, Epac1 is released from 
RanBP2 during mitosis, which correlates with a mobility shift 
Discussion
cAMP is a second messenger that is essential for relaying hor­
monal responses in many biological processes. Spatial regula­
tion of cAMP signaling is established by local degradation of 
cAMP by spatially restricted phosphodiesterases and, further­
more, by the confined targeting of the cAMP effector proteins. 
We have previously described several aspects of the spatiotem­
poral control of the cAMP effector Epac1. Epac1 is released 
from autoinhibition by the binding of cAMP (de Rooij et al., 
1998; Rehmann, 2006, 2008), and in addition, diverse anchoring 
mechanisms, including plasma membrane targeting (Ponsioen 
et al., 2009; Gloerich et al., 2010), recruit Epac1 to specific sub­
cellular localizations. This compartmentalization of Epac1 re­
sults in local activation of Rap, which couples Epac1 signaling 
to specific cellular processes. We now show that Epac1, in ad­
dition, is negatively regulated by its interaction with the nucleo­
porin RanBP2. We found that Epac1 directly interacts with the 
ZNFs of RanBP2, which recruits Epac1 to the NPC. RanBP2 
Figure 5.  RanBP2 binds to the CDC25-HD of Epac1. 
(A) Domain architecture of Epac1 showing its catalytic 
region with the CDC25-homology domain (CDC25-HD) 
responsible for the catalysis of Rap, which is stabilized 
by the Ras exchange motif (REM) domain. In addition, 
the  catalytic  region  contains  a  Ras  association  (RA)   
motif.  The  regulatory  region  of  Epac1  contains  the 
cAMP-binding (CNB) domain and a Disheveled, Egl-10, 
and Pleckstrin (DEP) domain. (B) Coimmunoprecipita-
tion of endogenous RanBP2 with YFP-tagged full-length 
Epac1, the individual regulatory region (Reg Region), 
catalytic region (Cat Region), and the individual do-
mains from the catalytic region of Epac1 in HEK293T 
cells. The CDC25-HD of Epac1 mediates the binding 
to RanBP2. (C) Confocal live imaging of HEK293T cells 
transfected with the YFP-tagged individual regulatory 
region, catalytic region, and the individual domains 
from the catalytic region of Epac1. Both the catalytic 
region and the CDC25-HD localize to the nuclear en-
velope. (D) Confocal live imaging of HEK293T cells 
transfected with YFP-tagged Epac1 lacking its RA do-
main (YFP-Epac1-RA) together with CFP-tagged wild-
type Epac1 showing that Epac1 lacking its RA domain 
is recruited to the nuclear envelope similar to wild-type 
Epac1. To maintain structural integrity, the RA domain 
of Epac1 is replaced by the region linking the REM 
domain and the CDC25-HD of the RasGEF Sos, which 
lacks an RA domain. Bars, 10 µm. IB, immunoblot;   
IP, immunoprecipitation; TL, total lysate.JCB • VOLUME 193 • NUMBER 6 • 2011   1016
Figure 6.  RanBP2-binding inhibits GEF activity of Epac1. (A) Measurement of Epac1 activity in vitro. Rap1B was loaded with fluorescent mantGDP and the 
release of mantGDP by Epac11–148 (left) or Epac2 (right) in the presence of 10 µM cAMP was measured in real time in the absence or presence of 1 or 
10 µM of the zinc finger (ZNF) domain of RanBP2 (which, as shown in Fig. 2, targets Epac1 to the NPC in vivo). The presented data are representatives of 
three independent experiments. (B) Pull-down of Rap1-GTP from Ovcar3 cells upon stimulation for 5 min with 5 µM isoproterenol (iso) 60 h after transfection 
with control (scr, scrambled), RanBP2, or Epac1 siRNAs. The bottom blot shows the efficiency of the knockdown of RanBP2 and Epac1. The quantification 
shows the mean with standard deviation of Rap1 activity from four independent experiments. Statistical analysis was performed using a one-tailed Student’s 
t test. Asterisks indicate the p-value of the respective sample with the associated control sample. *, P < 0.006; **, P < 0.0003. (C) Adhesion of Ovcar3 cells 
transfected with control (scrambled), RanBP2, or Epac1 siRNAs. 60 h after siRNA transfection, cells were allowed to adhere to a fibronectin-coated surface 
for 45 min in the absence or presence of 5 µM isoproterenol, and adhesion was subsequently detected by the measure of endogenous phosphatase activ-
ity. Shown are mean data with standard deviation from three individual experiments, which were normalized to the adhesion of control siRNA-transfected 
cells. Statistical analysis was performed using a Student’s t test. Asterisks indicate the p-value of the respective sample with the associated control sample. 
*, P < 0.02; **, P < 0.0003. The minus signs indicate unstimulated cells. IB, immunoblot.1017 Inhibition of Epac1 by RanBP2 • Gloerich et al.
nuclear envelope. This effect might be indirect, as based on our 
structural understanding of Epac, this mutant also comprises parts 
of the REM domain, which stabilizes the CDC25­HD. Third, the 
ZNF region of RanBP2 that is targeted to the plasma membrane 
by addition of the CAAX motif of K­Ras is able to recruit Epac1 
to the plasma membrane (Fig. 2 E), whereas RanV19­CAAX is 
not able to do so (Fig. S5). Because RanBP2 binding inhibits 
Epac1 activity (Fig. 6), this indicates Epac1 is kept at the NPC 
in an inactive state. In line with this, we have previously shown 
that cAMP­Epac1 signaling activates Rap predominantly at the 
plasma membrane and not at the nuclear envelope (Ponsioen et al., 
2009). Indeed, siRNA­mediated depletion of RanBP2 releases 
Epac1 from the NPC and enhances cAMP­induced Rap activa­
tion and cell adhesion (Fig. 6). Thus, RanBP2 maintains an in­
active pool of Epac1 at the NPC.
Our data indicate that phosphorylation of the ZNFs and, 
consequently, their decrease in affinity for Epac1 occurs in mi­
tosis when the NPC is broken down (Fig. 5). RanBP2 is pivotal 
for various aspects of mitosis, which involves both its E3 SUMO 
ligase as well as adaptor protein function, and ablation of RanBP2 
function results in various mitotic defects (Salina et al., 2003; 
Joseph et al., 2004; Prunuske et al., 2006; Dawlaty et al., 2008; 
Klein et al., 2009; Splinter et al., 2010). Potentially, the libera­
tion of Epac1 from RanBP2 may be a prerequisite for proper 
mitosis to take place, as release of Epac1 may allow the binding 
of other proteins to the ZNFs. For instance, binding of the co­
atomer complex COPI to the ZNFs of RanBP2 has been impli­
cated in nuclear envelope breakdown (Prunuske et al., 2006). 
Alternatively, RanBP2­released Epac1, itself, may contribute to 
aspects of this phase of the cell cycle. cAMP levels rapidly drop 
during the onset of mitosis and rise again during the transition 
into interphase (Grieco et al., 1996), which would restrict a role 
for RanBP2­released Epac1 and, consequently, Rap1 activation 
to the end of mitosis. In line with this, it was recently demon­
strated that Rap1 activity is required for respreading of rounded 
cells at the end of mitosis (Dao et al., 2009), which may involve 
its activation by Epac1.
In summary, we have demonstrated the regulated re­
cruitment of Epac1 to the NPC by RanBP2, thereby main­
taining an inactive cellular pool of Epac1. RanBP2 might 
function as a generic node that transduces different cellular 
inputs to regulate the availability of Epac1 and, consequently, 
to modulate the cAMP­Epac1­Rap1–signaling network. Very 
recently, it was shown for the Dbl family of Rho GEFs that 
binding of myosin II to its catalytic site suppresses GEF ac­
tivity (Lee et al., 2010). This implies that the formation of 
inhibitory protein complexes mediated by the catalytic do­
main might represent a common mechanism for the regula­
tion of GEFs.
Materials and methods
Reagents and antibodies
007 was obtained from Biolog Life Sciences; isoproterenol, nocodazole, 
taxol, thymidine, and noscapine were obtained from Sigma-Aldrich; OA 
was obtained from Enzo Life Sciences; and -phosphatase was obtained 
from New England Biolabs, Inc. The following antibodies were used: 
mouse monoclonal GFP (Roche), Flag M2 (Sigma-Aldrich), rabbit polyclonal 
of RanBP2 as well as of the individual ZNF of RanBP2. Sec­
ond, both this decrease in electrophoretic mobility and the re­
lease of Epac1 can be reverted by incubation with ­phosphatase. 
Finally, the phosphatase inhibitor OA induces the release of 
Epac1 from the NPC by elevating the phosphorylation state of 
the ZNFs. Thus, phosphorylation of the ZNFs is the most likely 
trigger to induce the release of Epac1 from RanBP2. Currently, 
the involved residues within RanBP2 are elusive, but because 
RanBP2 contains multiple ZNFs, it is likely that multiple phos­
phorylation sites are involved. Several phosphorylation sites 
have been reported within the ZNFs of RanBP2 (Beausoleil   
et al., 2004; Dephoure et al., 2008; Gauci et al., 2009; Mayya   
et al., 2009), but a more detailed analysis is required to identify 
the critical sites for Epac1 release and the involved upstream   
kinases. In addition to the phosphorylation of RanBP2, alterna­
tive mechanisms may also induce the release of Epac1 from the 
NPC. For instance, the DNA­binding capacity of ZNFs within 
transcription factors can be regulated by the oxidation of the zinc­
binding cysteines (Webster et al., 2001), and a similar mecha­
nism may exist for RanBP2.
Our results show that depletion of RanBP2 results in an in­
crease in cAMP­induced Epac1­dependent Rap1 activation and, 
consequently, cell adhesion, which is in accordance with a func­
tion for RanBP2 as a negative regulator of Epac1. One intriguing 
question is why this inactive pool of Epac1 is maintained at the 
NPC. Potentially, RanBP2 might contribute further to the regu­
lation of Epac1 than merely inhibiting its GEF activity. RanBP2 
functions as an E3 SUMO ligase (Pichler et al., 2002); how­
ever, thus far, we were unable to detect sumoylation of Epac1 
by RanBP2 in vivo or in vitro (unpublished data). RanBP2 also 
plays a role in nuclear import (Yaseen and Blobel, 1999; Hutten 
et al., 2008, 2009); however, RanBP2 likely does not control 
nuclear import of Epac1, as Epac1 remains nuclearly localized 
in cells depleted of RanBP2 (Fig. 2, A and B). Alternatively, 
Epac1 itself may function at the NPC independent of its Rap 
nucleotide exchange activity: for instance, by directly affecting 
the function of RanBP2 in nuclear import or sumoylation or as 
an adaptor protein to recruit additional proteins to the NPC. In­
deed, several Rap­independent effects of Epac1 have previously 
been described (López De Jesús et al., 2006; Métrich et al., 2008; 
Sehrawat et al., 2008). Finally, Epac1 may exert a local function 
at the NPC upon its release from RanBP2.
Recently, it was suggested that the localization of Epac1 
at the NPC is mediated by binding of its putative RA domain to 
the NPC­associated small G protein Ran (Liu et al., 2010). Our 
results, however, show that RanBP2 is the anchor for Epac1 at 
the  NPC  and  that  RanBP2  functions  independently  of  Ran. 
First, siRNA­mediated depletion of RanBP2 completely dis­
rupts the presence of Epac1 at the nuclear envelope (Fig. 2), 
whereas siRNA­mediated depletion of Ran does not show any 
effect on the localization of Epac1 at the nuclear envelope 
(Fig. S4). Second, the individual CDC25­HD of Epac1 local­
izes to the nuclear envelope, whereas the individual RA domain 
is not able to do so (Fig. 2 C). In addition, Epac1 lacking its 
RA domain is targeted to the nuclear envelope similar to wild­type 
Epac1 (Fig. 2 D). Using a distinct RA domain mutant, Liu et al. 
(2010) did observe effects on the localization of Epac1 at the JCB • VOLUME 193 • NUMBER 6 • 2011   1018
Confocal microscopy
For  visualization  of  YFP-Epac1  and  RanBP2  in  fixed  cells,  cells  were 
grown on 12-mm glass coverslips (for experiments with HEK293T, cells 
were precoated with poly-l-lysine [Sigma-Aldrich]), fixed with 3.8% form-
aldehyde, permeabilized using 0.1% Triton X-100, and blocked in 2% 
BSA. For visualization of endogenous Epac1, cells were fixed in ice-cold 
methanol followed by 3.8% formaldehyde. Cells were incubated with 
the indicated primary antibodies and, subsequently, with Alexa Fluor– 
conjugated secondary antibodies (Invitrogen). Mounted slides were ex-
amined using a confocal laser-scanning microscope (Axioskop2; Carl 
Zeiss; 63× magnification lenses, NA 1.4). For live imaging, transfected 
cells were grown in Willco wells (Willco Wells B.V.) and examined at 
37°C in L-15 medium (Leibovitz; Sigma-Aldrich) using an confocal laser-
scanning microscope (Axioskop2; 63× magnification lenses, NA 1.4). 
Postacquisition  image  adjustments  were  performed  using  ImageJ  soft-
ware (National Institutes of Health).
In vitro Rap activation assay
Loading of Rap with the fluorescent GDP analogue mantGDP (2-/3-O-
[N-methylanthraniloyl]guanosine-5-O-diphosphate) and the general assay 
set up were performed as previously described (Rehmann, 2006) but with   
10 µM ZnCl2 in the reaction buffer. RanBP2 ZNF was added to the reaction 
at concentrations as indicated in the figures.
In vivo Rap activation assay
Rap activity was assayed as described previously (van Triest and Bos, 
2004). In brief, 60 h after siRNA transfection of Ovcar3 cells grown in 
6-well  plates,  cells  were  stimulated  for  5  min  with  5  µM  isoproterenol 
and, subsequently, lysed in buffer containing 1% NP-40, 150 mM NaCl,   
50 mM Tris-HCl, pH 7.4, 10% glycerol, 2 mM MgCl2, and protease and 
phosphatase inhibitors. Lysates were cleared by centrifugation, and active 
Rap was precipitated with a GST fusion protein of the Ras-binding domain 
of Ral guanine nucleotide dissociation stimulator precoupled to glutathione– 
Sepharose beads. Bound proteins were eluted in Laemmli buffer and ana-
lyzed by SDS-PAGE and Western blotting with the indicated antibodies.
Adhesion assay
Adhesion of Ovcar3 cells was measured as described previously (Lyle et al., 
2008). In brief, 48-well polystyrene cell culture dishes were precoated 
with 5 µg/ml fibronectin and, subsequently, blocked with bovine serum 
albumin (Sigma-Aldrich). 60 h after siRNA transfection, cells were trypsin-
ized, washed once in RPMI 1640 containing 10% FBS, and allowed to 
recover surface proteins for 1.5 h in suspension in RPMI 1640 containing 
0.5% FBS, glutamine, and 10 mM Hepes, pH 7.4, at 37°C with gentle 
rolling. Subsequently, 6.0 × 10
5 cells were plated per well in the absense 
or presence of 5 µM isoproterenol. Adhesion was allowed to proceed for 
45 min at 37°C, and unbound cells were discarded by washing with PBS. 
Adhered cells were lysed in buffer containing 0.4% Triton X-100, 50 mM 
sodium citrate, and 10 mg/ml phosphatase substrate (Sigma-Aldrich). The 
reaction was incubated at 37°C, and the total amount of cellular protein 
was determined by measuring the absorption at 405 nm.
Online supplemental material
Fig.  S1  shows  coimmunoprecipitation  of  RanBP2  with  Epac1.  Fig.  S2 
shows localization of YFP-Epac2 in HEK293T cells. Fig. 3 shows the 
coimmunoprecipitation of RanBP2 with Epac1 in cells arrested in mitosis 
by incubation with nocodazole, taxol, or noscapine. Fig. S4 shows the 
localization of YFP-Epac1 in cells depleted of Ran. Fig. S5 shows the local-
ization of CFP-Epac1 in cells expressing YFP-RanV19-CAAX. Online sup-
plemental material is available at http://www.jcb.org/cgi/content/full/ 
jcb.201011126/DC1.
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RanBP2  (Abcam),  Rap1  (Santa  Cruz  Biotechnology,  Inc.),  and  Ran 
(BD). The monoclonal Epac1 antibody (Cell Signaling Technology) has 
been described previously (Ponsioen et al., 2009). The goat polyclonal 
RanBP2 antibody was a gift from F. Melchior (Zentrum für Molekulare 
Biologie der Universität Heidelberg, Heidelberg, Germany) and has pre-
viously  been  described  (Pichler  et  al.,  2002).  The  rabbit  polyclonal 
Epac1 antibody (2293) was generated in house by injection of purified 
1–148-Epac1. ON-TARGETplus SMARTpool siRNAs targeting RanBP2 
(L-004746), Epac1 (L-007676), and Ran (L-010353) and control siRNAs 
were obtained from Thermo Fisher Scientific.
DNA constructs
Full-length Epac1 (RapGEF3, Homo sapiens; available from GenBank/
EMBL/DDBJ  under  accession  no.  3978530)  and  Epac2  (RapGEF4, 
Mus  musculus; available from GenBank/EMBL/DDBJ under accession 
no. 9790086), the separate regulatory (amino acids 1–328) and cata-
lytic (amino acids 330–881) region of Epac1, the individual REM (amino   
acids 330–486), RA (amino acids 487–593), and CDC25-HD (amino 
acids 598–867) of Epac1, and the ZNF domain (amino acids 1,341–
1,819)  and  individual  ZNF  (ZNF  #2;  amino  acids  1,407–1,456)  of 
RanBP2 were C-terminally cloned to either a Citrine YFP or Flag-His tag 
in a pcDNA3 vector or an HA tag in a pMT2 vector using the Gateway 
system  (Invitrogen).  cDNA  for  RanBP2  was  a  gift  from  T.  Nishimoto 
(Kanazawa  University  Cancer  Research  Institute,  Kanazawa,  Japan), 
and RFP-H2B was a gift from R. Medema (University Medical Center 
Utrecht, Utrecht, Netherlands). The YFP-RA-Epac1 mutant has been de-
scribed previously (Ponsioen et al., 2009). In this mutant, the RA domain 
between the REM and CDC25-HD of Epac1 has been replaced by the 
homologous region of the RasGEF Sos (which lacks an RA domain) to 
maintain the structural integrity of Epac1. The C-terminal CAAX motif of 
K-Ras (van der Wal et al., 2001) was used to generate the ZNF domain–
CAAX and RanV19-CAAX chimeras.
Yeast two-hybrid screening
Human full-length Epac1 cloned in a pB27 vector was screened with a ran-
domly primed human placenta library by Hybrigenics S.A. as previously 
described (Rain et al., 2001).
Protein purification
Rap1B (amino acids 1–167), Epac1 (amino acids 149–882), and Epac2 
(amino acids 280–993) proteins were purified as previously described 
(Rehmann, 2006; Rehmann et al., 2006). The ZNF domain was cloned into 
a pGEX6P3 vector (GE Healthcare) and expressed in the bacterial strain 
CK600K as previously described for Epac (Rehmann, 2006) but in medium 
supplemented with 100 µM ZnSO4. The protein was essentially purified as 
previously described for Epac (Rehmann, 2006), but all buffers were sup-
plemented with 10 µM ZnCl2, and instead of on column cleavage, the pro-
tein was eluted with 20 mM gluthatione, cleaved with PreScission Protease, 
dialyzed, and reloaded to a GST column to remove the cleaved GST.
Cell culture and transfection
HEK293T (human embryonic kidney) and U2OS (human osteosarcoma) cells 
were cultured in DME, and Ovcar3 (ovarian carcinoma) cells were cultured 
in RPMI 1640 medium. All media were supplemented with 10% FBS and 
antibiotics. Cells were transfected with expression plasmids using a transfec-
tion reagent (FuGENE; Roche) and with ON-TARGETplus SMARTpool siRNA 
using HiPerFect (QIAGEN) according to manufacturer’s protocol.
Coimmunoprecipitations
Immunoprecipitations were performed in lysis buffer containing 1% Triton 
X-100, 20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM MgCl2, and pro-
tease and phosphatase inhibitors. Cell lysates were cleared by centrifuga-
tion and incubated with protein A agarose beads (GE Healthcare) coupled 
to the indicated antibody. After extensive washing with lysis buffer, bound 
proteins were eluted in Laemmli buffer and analyzed by SDS-PAGE and 
Western blotting with the indicated antibodies. Where indicated (Fig. 4 D),   
cells were treated for 1 h with 1 µM OA before lysis. For coimmunopre-
cipitations in mitotic cells, cells were treated for 24 h with 2.5 mM thymi-
dine followed by extensive washing with PBS and 16-h incubation with 
250 ng/ml nocodazole, 2 µM taxol, or 25 µM noscapine. Mitotic cells 
were subsequently collected by mitotic shake off. The in vitro interaction 
between bacterially purified Epac1 and GST-tagged RanBP2 ZNF domain 
was performed in a buffer containing 100 mM NaCl, 5 mM dithiothreitol, 
2.5% glycerol, and 0.005% Tween using either protein A agarose beads 
coupled to the Epac1 antibody or glutathione agarose beads.1019 Inhibition of Epac1 by RanBP2 • Gloerich et al.
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